Jobs / United States / Astrazeneca Pharmaceuticals Lp
Transforming Care Lead – Cardiovascular, Renal and Metabolic (CVRM)
Astrazeneca Pharmaceuticals Lp · 🇺🇸 Field PS
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Position: Transforming Care Lead – Cardiovascular, Renal and Metabolic (CVRM) Location: Field-based, UK Competitive Salary & Excellent Company Benefits Applications Closing Date: 2 November 2026 Introduction to the Role At AstraZeneca UK, Medical & Scientific Affairs plays a pivotal role in improving patient outcomes by working collaboratively with NHS partners to support meaningful and sustainable changes in healthcare delivery. As Transforming Care Lead – Cardiovascular, Renal and Metabolic (CVRM), you will lead the development and implementation of the CVRM transforming care strategy. You will work in partnership with therapy area Medical and Brand teams to ensure NHS systems are ready to identify, diagnose and optimally manage relevant patients ahead of, and throughout, the launch period. Using population health and pathways expertise, you will help accelerate the implementation of guideline-directed care at scale. This will include identifying pathway, diagnostic and capacity gaps; prioritising opportunities using population health data; and driving improvements across clinical systems, medicines optimisation, care pathways and collaborative working models. The role operates on a non-promotional medical basis. You will work closely with Brand and Commercial colleagues while maintaining independent medical judgement and ensuring that any system changes supported are clinically appropriate, evidence-based and aligned with the needs of patients and NHS systems. Key Accountabilities Transforming Care Strategy and System Readiness You will partner with CVRM Medical and Brand teams to define the therapy area transforming care strategy and lead the development and delivery of system readiness plans for CVRM launches. This will involve assessing where pathway, diagnostic and capacity gaps exist, sequencing the changes required and reporting readiness status through launch governance. You will use linked datasets, secure data environments and NHS data partnerships to identify the populations and health systems where intervention is most likely to deliver meaningful impact. Your approach will be evidence-led, prioritising opportunities based on population need rather than responding solely to inbound requests. You will ensure that pathways, clinical systems, medicines optimisation and collaborative working initiatives are aligned to the transforming care strategy. You will also build a strong network of external expert partners, assess the external landscape for future collaboration opportunities and integrate new providers into local or national AstraZeneca UK projects where appropriate. A key part of the role will be gathering and interpreting population health analytics at national, system and local levels. You will ensure every transforming care initiative has a clearly defined evaluation approach, including agreed baselines and outcome measures at the design stage. Findings will be shared internally and, where appropriate, published or presented externally. You will be accountable for the CVRM transforming care budget, prioritising investment across initiatives to maximise system impact. Implementation of Population Health and Pathways Initiatives You will lead the implementation of population health and pathways initiatives across clinical systems, medicines optimisation, patient pathways and collaborative working models. This will require close coordination with field medical team managers and alignment across internal stakeholders, including Senior Leadership Team members, Franchise Heads and Heads of Medical. You will define, prioritise and communicate the Population Health and Pathways book of work, ensuring that activity is strategically aligned, appropriately resourced and clearly understood across the organ